It is well known that testosterone replacement leads to improvement of muscle mass and strength (13) and bone density (14, 15)

It is well known that testosterone replacement leads to improvement of muscle mass and strength (13) and bone density (14, 15). The clinical implications of low testosterone are diverse and include organizations with disposition, anemia, muscle mass and strength, bone mass, and sex function. Therapeutic options are controversial and include optimal management of kidney function, pharmacologic options, and testosterone replacement. The use of testosterone supplementation in particular Rhoa has significantly increased in the past few years. In the UK, the number of prescriptions to GW-1100 get testosterone replacement increased nearly 90% from 20012010. A number of these prescriptions were for the newer, more costly, formulations resulting in a nearly 300-fold increase in healthcare costs (3). Recently, testosterone replacement continues to be linked with increased cardiovascular riskthough this declare is controversial and continues to be disputed due to discrepancies in statistical analyses (4). Despite this widespread utilization of testosterone, data is missing concerning the overall health risks, benefits, and effectiveness. The data on use of testosterone in ESRD patients is even more limited. Low testosterone levels have been correlated with higher all-cause and cardiovascular-related mortality in dialysis patients (5) and low levels at the time of transplantation are associated with patient and graft loss (6). There is a dearth of information on the effect of testosterone therapy in ESRD and transplant patients. == Etiology of hypogonadism in ESRD patients == Hypogonadism in ESRD patients is likely multifactorial. Many patients possess comorbidities that can contribute to hypogonadism including diabetes, vascular disease, atherosclerosis, old age, and obesity. In addition to these pre-existing conditions, ESRD patients are in a chronically inflamed state; with documented elevated levels of inflammatory biomarkers (7). These factors are likely interrelated and ultimately culminate in changes to the hypothalamic-pituitary-gonadal axis. Though the process is complex and incompletely comprehended, there are several known disruptions including reduction of gonatotropin-releasing hormone (GNrH) and reduced amplitude of the resultant luteinizing hormone (LH) secretory burst (8). LH levels are raised in chronic kidney disease (CKD) patients due to reduced testosterone feedback, and testicular failure contributes to reduced testosterone levels. Follicle-stimulating hormone (FSH) levels are generally raised. In addition , prolactin levels in CKD patients are raised and resistant to suppression GW-1100 and can lead to suppression of the regular pulsatile release of GnRH (Table 1). == Table 1 . Biochemical disruptions in CKD patients. == CKD, chronic kidney disease; GNrH, gonatotropin-releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone. == Clinical presentation of hypogonadism == Hypogonadism can affect multiple systems with sex dysfunction maybe being most obvious presentation and includes low libido, difficulties with orgasm, low overall sex satisfaction, and erectile dysfunction (Table 2). Virtually all men with ESRD report some form of sex dysfunction with some studies reporting > 80% of ESRD patients affected. Several studies have reported significantly reduce quality of life scores on validated questionnaires (9, 10) and have shown diminished quality of both physical and mental aspects of life. == Table 2 . Clinical manifestations of hypogonadism. == The association between testosterone deficiency and anemia in CKD patients has recently been analyzed and testosterone levels were found to be negatively associated with hemoglobin levels in uni- and multivariate models (11). CKD patients were 5 times more likely to be anemic if they had low testosterone levels. There was an inverse association between testosterone levels and erythropoiesis-stimulating agents (ESAs) as well, making testosterone a possible target to get patients who also are hyporesponsive to ESAs. Many of these presentations however are nonspecific GW-1100 and can be found frequently in old patients with multiple comorbidities such as all those on dialysis. It can be difficult to differentiate the etiology of those manifestations. Treatment should be taken to ensure adequate nutrition, physical activity, strength building, and correction of anemia in all patients prior to attributing clinical demonstration to hypogonadism alone. Laboratory evaluation is critical to help discern the etiology. == Diagnosis == The diagnosis of hypogonadism is two-pronged and contains the laboratory detection of a low testosterone level and well because the corresponding signs and symptoms. It is important to be familiar with the laboratory assay being used at a particular institution as well as the reference ranges in order to appropriately interpret results. Total serum testosterone is usually.